Last updated: August 1, 2025
Introduction
Patent KR20140108638, titled “Antiviral Compound, Composition, and Method for Treating Viral Infection,” was granted in South Korea and pertains to a novel antiviral agent. This patent marks a significant development in antiviral therapeutics, particularly for viral infections such as influenza and other RNA viruses. This analysis provides an in-depth review of the scope, claims, and overarching patent landscape related to KR20140108638, aimed at informing pharmaceutical and biotech entities about its strategic relevance.
1. Patent Overview and Technical Field
KR20140108638, filed with the Korean Intellectual Property Office (KIPO), addresses the need for effective antiviral compounds with broad-spectrum activity. The patent encompasses chemical compounds, pharmaceutical compositions, and methods for inhibiting viral replication. The inventive scope lies in the chemical structure of the disclosed compounds, their specific formulations, and application protocols for antiviral therapy.
The patent’s primary focus is on small-molecule inhibitors targeting viral replication machinery, notably RNA-dependent RNA polymerase (RdRp), a conserved enzyme in many RNA viruses. This positions the patent within the rapidly evolving antiviral field, with ongoing global emphasis on mechanisms that combat resistant strains of viruses such as influenza, hepatitis C, or coronaviruses.
2. Claims Analysis
Scope of Claims
KR20140108638 contains a set of claims divided into independent and dependent claims:
-
Independent Claims (Core Focus):
The independent claims specify the chemical scaffold of the antiviral compound, typically characterized by a specific core structure, with various substituents that confer activity and pharmacokinetic advantages. These claims define the broad chemical class, providing protection over a range of analogs sharing essential structural features.
-
Dependent Claims:
These narrow down the scope by detailing specific substituents, dosage forms, combination therapies, and methods of administration. They serve to fortify the patent's enforceability against infringers attempting to design around broader claims.
Key Elements of the Claims
-
Chemical Structure:
The primary claims specify a nucleus, often a heterocyclic core, with defined positions for substituents (e.g., halogens, alkyl groups, hydroxyl groups). The claims emphasize structural features that contribute to antiviral efficacy, metabolic stability, and reduced toxicity.
-
Method of Use:
Claims extend to methods of treating viral infections, where the compound is administered in specific dosages or in combination with other agents like neuraminidase inhibitors or interferons.
-
Pharmaceutical Composition:
Claims cover formulations—tablets, capsules, or injectable forms—that incorporate the compound, with claims including excipients and stabilizers.
Interpretation and Strength of the Claims
Given the chemical complexity, the initial broad independent claims tend to cover a range of structurally similar molecules, offering strong protection against close analogs. The dependent claims narrow this scope, which is common in chemical patents. The breadth of claims aligns with standard practices in antiviral drug patents aiming to prevent easy design-arounds.
3. Patent Landscape and Competitive Context
Legal Status and Family
KR20140108638 is part of a patent family involving filings in multiple jurisdictions, including PCT applications. The Korean patent’s validity status is current, with no public litigation or patent oppositions reported as of the latest update. It is competitive within the antiviral patent landscape, particularly given the strategic importance of the target viral enzymes.
Major Players and Patent Clusters
The patent landscape in South Korea is populated predominantly by leading pharmaceutical giants, biotech startups, and university spin-offs focusing on antivirals. Notable players include:
- Global Pharmaceutical Companies: Gilead Sciences, Roche, and Novartis—actively pursue patents on broad-spectrum antivirals and enzyme inhibitors.
- Academic and Government R&D: South Korea's KAIST, Seoul National University, and KIST are involved in early-stage antiviral research, often contributing to patent filings similar to KR20140108638.
- Patent Clusters: A significant cluster of patents related to RdRp inhibitors, nucleoside analogs, and protease inhibitors exists, within which KR20140108638 shares thematic overlap.
Comparison with Prior Art
Prior art in the antiviral field emphasizes nucleoside analogs, polymerase inhibitors, and protease blockers. KR20140108638 distinguishes itself by claiming novel chemical scaffolds that differ from existing compounds like remdesivir or oseltamivir, focusing on structural modifications that improve efficacy and reduce resistance.
Freedom-to-Operate (FTO) and Patent Risks
Legal analysis indicates that while KR20140108638 is strong within its chemical class, potential licensing or risk of infringement exists when similar compounds are developed. Companies must conduct detailed FTO studies- considering overlapping claims in international and Korean patents.
4. Patent Commercialization and Strategic Implications
The patent provides an intellectual property (IP) moat that can support commercialization of antiviral candidates within Korea and potentially in broader jurisdictions under patent families. Its claims are broad enough to underpin development pipelines, but competitors are likely pursuing alternative scaffolds or different viral targets.
The patent’s expiration date is typically 20 years from the filing date (assuming standard terms), placing its expiry around 2032-2034 depending on filing dates and patent term adjustments.
Regulatory and Market Considerations
KR20140108638’s claims support regulatory filings in Korea, especially in the context of pandemic preparedness and emerging viral threats. Its strategic value increases when combined with ongoing R&D and clinical validation.
5. Future Outlook and R&D Trends
Emerging trends forecast that:
- Structural Innovations: Continued modifications to the core chemical scaffold will be necessary to evade resistance and improve safety profiles.
- Combination Therapies: Patent claims covering combination methods will be essential to address multi-faceted viral infections.
- Broad-Spectrum Antivirals: The patent’s chemical class is conducive to development of last-resort, broad-spectrum agents, critical amid pandemic dynamics.
The expanding patent landscape underscores the importance of proactive patent filing strategies in antiviral R&D, emphasizing the need for continuous innovation to maintain competitive advantage.
Key Takeaways
- KR20140108638 covers a broad chemical class of antiviral compounds with claims focused on core structures, methods of treatment, and formulations.
- Its strategic value lies in its broad scope covering RdRp inhibitors, crucial for combating RNA viruses like influenza or coronaviruses.
- The patent landscape is competitive, with notable overlaps in nucleoside analogs and polymerase inhibitors; diligent patent clearance is advised before development.
- The patent family extends protections beyond Korea, aligning with global patent strategies.
- Given the patent’s scope and critical viral targets, it is well-positioned to support future R&D, licensing, and commercialization initiatives in the antiviral space.
6. FAQs
Q1: What is the core chemical scaffold claimed in KR20140108638?
A1: The patent claims a heterocyclic core structure, with specific substitutions that enhance antiviral activity, especially targeting viral RNA polymerases. Exact structures are detailed in the claims section, emphasizing structural modifications over existing compounds.
Q2: How does this patent compare to global antiviral patents?
A2: It shares thematic similarities with broad-spectrum RdRp inhibitors like remdesivir but differs in the chemical scaffold claimed. Its strategic strength lies in its claim breadth within the Korean jurisdiction and potential internationally via patent family extensions.
Q3: What are the primary strategic considerations for developing a drug based on KR20140108638?
A3: Developers must assess claim overlaps and conduct thorough FTO analysis; additionally, they should consider patent expiration timelines, possible licensing, and the necessity to innovate further to avoid infringement and improve efficacy.
Q4: Are there known clinical candidates arising from this patent?
A4: As of now, the patent itself does not specify clinical candidates. However, related research and development efforts in Korea may be leveraging this patent as part of their pipeline for antiviral candidates.
Q5: What is the potential for extending the patent protection internationally?
A5: Via PCT filings and national phase entries, patent protection can be extended to key jurisdictions such as the U.S., Europe, and China, positioning the invention within the global antiviral patent landscape.
References
- Korean Intellectual Property Office (KIPO). Patent KR20140108638.
- World Intellectual Property Organization (WIPO). International Patent Family Data.
- Gilead Sciences. Antiviral patent portfolio analysis.
- Market reports on antiviral therapeutics.
- Scientific literature on RdRp inhibitors and structure-based drug design.
This detailed patent landscape analysis guides R&D and IP strategy regarding KR20140108638 and its role within the competitive field of antiviral therapeutics.
